SF3B1mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution

Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome

(2014) T-C Chen et al.   Blood Cancer Journal

Clinical implications of theSETBP1mutation in patients with primary myelodysplastic syndrome and its stability during disease progression

(2013) Hsin-An Hou et al.   AMERICAN JOURNAL OF HEMATOLOGY

IDHmutations are closely associated with mutations ofDNMT3A,ASXL1andSRSF2in patients with myelodysplastic syndromes and are stable during disease evolution

(2013) Chien-Chin Lin et al.   AMERICAN JOURNAL OF HEMATOLOGY

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes

(2012) F. Damm et al.   BLOOD

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

(2012) F. Thol et al.   BLOOD

Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms

(2012) M. Cazzola et al.   BLOOD

The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution

(2012) S.-J. Wu et al.   BLOOD

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

(2012) Rafael Bejar et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts

(2012) Rui Cui et al.   LEUKEMIA RESEARCH

SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value

(2011) M. M. Patnaik et al.   BLOOD

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

(2011) L. Malcovati et al.   BLOOD

DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications

(2011) H.-A. Hou et al.   BLOOD

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

(2011) D. Rossi et al.   BLOOD

Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes

(2011) Rafael Bejar et al.   JOURNAL OF CLINICAL ONCOLOGY

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

(2011) F Damm et al.   LEUKEMIA

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

(2011) M J Walter et al.   LEUKEMIA

Frequent pathway mutations of splicing machinery in myelodysplasia

(2011) Kenichi Yoshida et al.   NATURE

Mutations in RNA Splicing Machinery in Human Cancers

(2011) Benjamin Ebert et al.   NEW ENGLAND JOURNAL OF MEDICINE

SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts

(2011) E. Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system

(2010) H.-A. Hou et al.   BLOOD

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

(2010) Thomas Ernst et al.   NATURE GENETICS

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations

(2009) J.-L. Tang et al.   BLOOD